exas stock: Exact Sciences Corporation Overview

This article explains exas stock (Exact Sciences Corporation) — a NASDAQ‑listed diagnostics company — covering company background, products, financials, stock data, analyst views, risks, and how in...

2024-07-04 05:09:00

By Nexus Link

Article rating

4.2

106 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EXAS (Exact Sciences Corporation) — Stock

exas stock is the ticker symbol for Exact Sciences Corporation, a publicly traded diagnostics and cancer‑screening company listed on NASDAQ. This article focuses on the equity (not a cryptocurrency), offering investor‑relevant background, product and pipeline context, market and stock information, analyst coverage, risks, and practical guidance for following EXAS as an investor. Read on to understand what drives the company’s revenue and valuation, what material events have recently affected the shares, and where to check up‑to‑date market data.

Company overview

Exact Sciences Corporation (ticker: EXAS) is a U.S. molecular diagnostics company founded in 1995 with headquarters in Madison, Wisconsin.

The company’s core mission is early cancer detection and precision oncology using non‑invasive molecular tests and laboratory services. Exact Sciences’ primary commercial offerings historically included the stool‑based Cologuard colorectal cancer screening test and, following acquisitions, cancer prognostic and predictive tests such as Oncotype DX for breast and prostate cancer. Exact Sciences also invests in liquid biopsy and other blood‑based assays aimed at minimal residual disease (MRD) detection and multi‑cancer early detection (MCED).

Corporate history and milestones

Exact Sciences was founded in 1995 and transitioned over time from R&D to commercialization of screening diagnostics. Major corporate milestones that materially affected the company and its stock include regulatory approvals and product launches, strategic acquisitions, and corporate partnerships.

Notable milestones:

Cologuard launch and commercial rollout after regulatory and payer milestones that established the first large‑scale, non‑invasive stool DNA colorectal cancer screening option in the U.S.
Acquisition of Genomic Health (which operated the Oncotype DX business), expanding Exact Sciences into tissue‑based genomic tests for cancer prognosis and treatment guidance.
Ongoing R&D and clinical programs in MRD and MCED, positioning the company for future blood‑based screening opportunities.
Material corporate events such as licensing agreements, payer coverage decisions, and, most recently, acquisition activity reported in the financial press (see Recent developments).

Business model and revenue drivers

Exact Sciences generates revenue primarily by selling diagnostic tests and associated laboratory services. Key revenue streams include:

Screening tests: Retail and physician‑ordered tests such as Cologuard for colorectal cancer screening generate per‑test revenue and are sensitive to screening adoption and physician recommendations.
Diagnostic and prognostic tests: Tissue‑based assays (e.g., Oncotype DX) billed to insurers, hospitals, and providers for treatment decision support in oncology.
Lab services and partnerships: Contract testing, collaborations, and potential licensing streams as the company expands its platform.

Revenue drivers and dynamics investors watch include payer reimbursement policies, U.S. population screening rates, international expansion success, price and volume trends, and the commercial progress of MRD/MCED tests. Reimbursement dynamics and coding/coverage decisions from payers materially affect unit economics for diagnostic tests.

Products and pipeline

Exact Sciences’ product portfolio and clinical pipeline shape investor expectations for growth and future profitability.

Main commercial products

Cologuard — a stool DNA test designed for average‑risk colorectal cancer screening. Cologuard has been a central revenue driver after receiving regulatory and payer support that broadened market access.
Oncotype DX (from the Genomic Health acquisition) — tissue‑based genomic assays providing prognostic and predictive information, especially in breast and prostate cancer care.
Other lab‑based oncology tests and ancillary services that complement the core offerings and support clinician workflows.

R&D pipeline

Research and development priorities include:

Minimal Residual Disease (MRD) assays — highly sensitive blood tests intended to detect small amounts of tumor DNA after treatment, supporting recurrence monitoring and therapy decisions.
Multi‑Cancer Early Detection (MCED) — blood tests that attempt to detect multiple cancer types at earlier stages. Success in MCED could create a large new addressable market but is subject to clinical validation, regulatory review, and payer decisions.
New assay development and platform improvements to increase sensitivity, specificity, and operational scale.

The relative contributions of established tests (Cologuard, Oncotype DX) versus future blood‑based assays inform valuations and investor sentiment, since MCED or MRD commercialization would materially expand revenue potential but require significant investment and regulatory milestones.

Market position and competition

Exact Sciences competes in diagnostics and precision oncology with multiple peers across different test modalities. Competitors include companies focused on liquid biopsies, genomic testing, and laboratory services.

Key competitive and market‑share considerations:

Colorectal screening space: Cologuard competes against colonoscopy (the clinical gold standard), FIT tests, and other screening modalities. Adoption depends on physician guidance, patient preference, and payer coverage.
Liquid biopsy and MCED competition: Firms developing blood‑based tests for MRD or MCED (with various technological approaches) represent a direct competitive set. Differentiation depends on sensitivity, specificity, clinical validation, and commercial reach.
Diagnostic lab services and genomics peers: Companies offering tissue‑based genomic assays or laboratory services compete on scientific validity, clinician adoption, and payer support.

Competitive risks arise from superior technology, more favorable reimbursement, or faster commercialization by peers. Market penetration also depends on physician education, guideline endorsements, and public screening programs.

Stock information

Ticker and listing: EXAS on the NASDAQ exchange (U.S. dollars).

Typical investor‑facing facts to monitor for exas stock include shares outstanding, float, market capitalization, average trading volume, and 52‑week high/low. These metrics are time‑sensitive; investors should consult primary sources such as company SEC filings and major finance portals for current figures.

As of January 2026, financial media price snapshots showed EXAS trading around the low‑three‑figure range per share. For example, market data published in early 2026 cited EXAS near $102 per share; please confirm the exact price and market cap on a real‑time quote source when making decisions.

Suggested sources for up‑to‑date quotes and detailed share statistics: Nasdaq official quotes, Yahoo Finance, Morningstar, CNBC, and company SEC filings (Form 10‑Q and Form 10‑K) via EDGAR. These sources provide shares outstanding, float, market capitalization, and typical trading volume at specific dates.

Historical price performance

Historical price charts for exas stock are typically presented as daily, weekly, or monthly price series with volume. Notable historical moves are often tied to published earnings, major clinical or regulatory announcements, acquisitions, and large analyst rating changes.

Investors commonly examine multi‑year charts to understand volatility, drawdowns, and recovery phases associated with company milestones (e.g., product launches or M&A activity). Events that have historically moved EXAS shares include quarterly earnings beats or misses, payer coverage developments, major R&D readouts, and M&A rumors or announcements.

Dividends, splits and corporate actions

Exact Sciences historically has focused capital on growth and R&D rather than paying dividends to shareholders. Investors should review recent company releases and SEC filings to confirm whether the company pays dividends or has authorized stock buybacks, secondary offerings, or other capital‑markets transactions.

Large corporate actions—acquisitions, significant equity raises, and share repurchase programs—can dilute or alter the capital structure and therefore affect exas stock metrics. Refer to the company’s investor relations materials and SEC filings for authoritative records of corporate actions and dates.

Financial performance

Investors tracking exas stock typically focus on revenue trends, gross margins, operating losses or profits, EPS, cash flow from operations, and balance‑sheet metrics such as cash and debt levels.

Relevant financial themes for Exact Sciences include:

Top‑line growth driven by test volume expansion and price or mix changes between screening and diagnostic products.
Path to profitability: the tradeoff between sustained investment in R&D and commercialization of MRD/MCED versus operating leverage from established products.
Cash burn and financing: capital needs to fund clinical trials, commercial expansion, and lab capacity are important for assessing dilution risk.
Key valuation ratios: price‑to‑sales (P/S) is commonly used for growth‑stage diagnostics firms; price‑to‑earnings (P/E) may be less meaningful if the company is not consistently profitable.

For verified figures (revenue by period, EPS, cash, and debt), consult the latest Form 10‑Q or Form 10‑K and audited financial statements. Quarterly earnings releases and investor presentations summarize trends and management guidance that can materially influence exas stock volatility.

Analysts, ratings and price targets

exas stock is covered by multiple sell‑side analysts. Common analyst metrics include consensus rating distribution (Buy/Outperform, Hold/Neutral, Sell/Underperform), median price targets, and the rationale underlying recommendations.

As an example of timely analyst activity, media reporting in early 2026 noted that a Wall Street analyst revised coverage of Exact Sciences: Mizuho changed its rating from Outperform to Neutral and adjusted its price target (reported as a raise from $85 to $105), reflecting evolving views on risk and valuation. Investors should track such rating changes and read analyst reports for their assumptions about revenue growth, margin improvement, and the timing of MRD/MCED commercialization.

Analyst commentary typically centers on two themes: (1) growth potential from broader screening adoption and blood‑based tests, and (2) near‑term execution risks and capital requirements that may pressure margins. Consensus price targets and rating distributions are useful snapshots but change quickly after material events.

Major shareholders and insider ownership

Institutional ownership is an important factor for exas stock. Large institutional holders (mutual funds, ETFs, and pension funds) and insider ownership can signal confidence or create potential selling pressure in the event of ownership reallocations.

To see the most recent list of top institutional holders, percent ownership, and insider transactions for Exact Sciences, consult the company’s latest proxy statement (DEF 14A) and quarterly filings, along with up‑to‑date share‑ownership screens on financial data providers. SEC Form 4 filings disclose insider purchases and sales, which some investors monitor for potential signals about management sentiment.

Recent developments and news (investor‑relevant)

As of January 2026, according to financial media coverage, there were material corporate developments involving Exact Sciences that affected exas stock.

Notable recent items (dates referenced where available):

Acquisition announcement: As of January 2026, media reports cited that Abbott Laboratories announced in November 2025 a deal to acquire Exact Sciences for approximately $21 billion. This deal, reported across financial outlets, represents a major corporate action that would change ownership structure and valuation for EXAS shareholders. Investors should consult the definitive acquisition filings and company announcements for exact deal terms and closing conditions.
Analyst reactions: Following acquisition reports and other news, analysts updated ratings and price targets; for example, Mizuho revised its rating and increased a price target in early 2026 (reported in market coverage).
Earnings and guidance: Quarterly earnings reports and related guidance continue to move exas stock, particularly commentary on test volumes, reimbursement trends, and progress in MRD/MCED studies.
Regulatory and payer developments: FDA interactions, coverage policies from major payers, and changes in clinical guidelines materially influence the commercial outlook for screening and diagnostic products.

Because recent developments can rapidly change valuations and strategic direction, investors should update their view with primary sources such as company press releases, SEC filings, and verified regulatory announcements.

Risks and controversies

Principal risks for exas stock include the following categories—each can materially affect future revenue and valuation:

Reimbursement and payer risk: Reduced coverage, lower reimbursement rates, or unfavorable coding decisions can materially lower revenue per test.
Regulatory risk: FDA actions or delays in approvals for new assays (particularly MRD or MCED) can postpone commercialization and associated revenue.
Competition: Rival MCED and liquid biopsy developers could capture market share if they demonstrate superior clinical performance or achieve faster payer acceptance.
Execution risk: Commercial rollout of new assays, lab scale‑up, and effective physician/patient adoption are operational risks.
Litigation and compliance: Diagnostic companies face legal and regulatory compliance risks, including potential patent disputes, false‑claims exposure related to billing, or laboratory‑practice regulatory issues.
Macro and market risk: Broader market volatility, interest rate changes, and investor sentiment toward growth biotech/diagnostics stocks influence share price movements.

Investment considerations

This section provides a neutral summary of common investment perspectives on exas stock. It is informational and should not be construed as investment advice.

Investor bull case highlights:

Established commercial products (Cologuard, Oncotype DX) provide a revenue base and existing payer relationships.
Successful commercialization of MRD and MCED could create large new revenue streams and significantly expand the company’s addressable market.
Strategic partnerships, acquisitions, or favorable M&A outcomes (including reported acquisition interest) could unlock shareholder value.

Investor bear case highlights:

Heavy investment requirements for clinical validation, lab scale‑up, and commercialization may delay profitability and increase dilution risk.
Payer resistance or unfavorable reimbursement changes could limit revenue growth even if tests demonstrate clinical utility.
Strong competition in liquid biopsy and MCED could compress market share and pricing power.

Neutral considerations:

Valuation metrics must be interpreted in the context of growth prospects and capital intensity. Price‑to‑sales ratios, cash runway, and projected margin expansion are commonly used to balance expectations.
Material corporate events (e.g., announced acquisitions or definitive deal closings) can significantly change risk/return dynamics for exas stock.

Disclaimer: This article provides factual and contextual information only and is not investment advice or a recommendation to buy or sell exas stock. Investors should conduct independent due diligence and consult licensed financial professionals for personalized advice.

How to follow the stock

Practical pointers for monitoring exas stock include the following sources and metrics:

Real‑time quotes and charts: Use major finance portals or brokerage platforms for live pricing, intraday charts, and historical performance. Check the timestamp on any quoted price.
SEC filings: Review Form 10‑Q, Form 10‑K, Form 8‑K, and Form 4 for official financials, material event disclosures, and insider transactions.
Company investor relations: Earnings releases, investor presentations, and conference call transcripts provide management commentary and guidance.
Analyst coverage and research notes: Analyst revisions, rating changes, and model updates often follow material news and earnings.
Regulatory and payer updates: FDA announcements, CPT coding decisions, and payer coverage policies are critical for diagnostic test commercialization.
Monitor specific metrics: test volumes and revenue per test, gross margin trends, operating cash flow, cash runway, debt levels, and any announced capital raises or buybacks.

If you trade or follow exas stock through an exchange‑listed broker or platform that supports U.S. equities, check whether your provider requires account eligibility for particular services. For users of Bitget’s trading services, verify availability and local regulatory permissions for trading or accessing equity products via Bitget.

References

Primary references to consult for verification and the latest data include the following types of sources (specific provider examples used widely in market coverage): market data pages on Yahoo Finance and Morningstar, business and market reporting from CNBC and CNN Markets, analyst notes and research summaries (Zacks, MarketWatch, Investor's Business Daily), brokerage platforms’ security pages (Robinhood style data), and company SEC filings and investor relations disclosures.

As of January 2026, media reports (financial outlets and market data providers) covered a reported acquisition and analyst rating updates affecting EXAS. For example: “As of January 2026, according to Benzinga reporting, Abbott Laboratories announced in November 2025 a $21 billion buyout of Exact Sciences Corp (NASDAQ:EXAS).” Investors should review the original press releases and SEC filings for precise dates, deal terms, and closing conditions.

External links

For timely, authoritative information, consult the following categories of primary sources (search for the company name and ticker on these services): Exact Sciences investor relations pages, SEC EDGAR filings (10‑K, 10‑Q, 8‑K), Nasdaq quote pages for EXAS, and major financial data providers’ security pages (e.g., Yahoo Finance, Morningstar, CNBC). When using third‑party research, verify the date and cite primary filings for definitive figures.

Notes and maintenance guidance

Stock data—price, market capitalization, shares outstanding, float, and ratios—are time‑sensitive. Any quoted figure must include a date and source. Maintain editorial updates to this article after quarterly earnings releases, material regulatory decisions, and major corporate actions such as acquisitions or divestitures.

Editors and contributors should rely on company SEC filings for definitive financials and capital‑structure details and use reputable market data services for current pricing and shares outstanding. Flag and update any section that references a specific price, analyst target, or market metric within 24–72 hours of a material market event.